8/27/2012 7:32:44 AM
Teva Pharmaceutical Industries Ltd. (TEVA) is recruiting about 1,800 patients for a new trial of its multiple sclerosis pill in a bid to improve how the disease is treated and secure a successor to its best-selling medicine. The drug, laquinimod, is undergoing a third round of research with a new focus on slowing a patient’s descent into disability after failing to beat competing products on the industry standard of reducing the rates at which they experience relapses. Teva is testing the pill, shown to be safe in earlier trials, at a higher dose as it seeks to verify that the drug effectively delays loss of muscle control and balance.
comments powered by